Forecast

There is no analyst data available for this company.

News Go to news feed

Coloplast A-S (B) announces quarterly results for period to 30 June 2026

Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » More on finanzen.net
Coloplast A-S (spons ADRs) announces quarterly results for June 30, 2026

Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » More on finanzen.net
Coloplast expects significantly higher EPS and moderate revenue increase for Q3

Coloplast will publish results on 18 August 2026 for the quarter ended 30 June 2026. Ten analysts estimate EPS on average at 6.14 DKK versus 3.57 DKK in the year‑ago quarter. Thirteen analysts forecast a revenue increase of 4.3 percent to about 7.26 billion DKK. For the fiscal year, the average forecasts are 24.95 DKK EPS and around 28.77 billion DKK in revenue. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, COLOPLAST has already paid €0.67 in dividends. The last payout was in May.

Financials

In the last quarter, COLOPLAST had revenue of €7.34B and net profit of €1.46B

(EUR)	June 2026	YoY
Revenue	7.34B	5.43%
Gross profit	4.9B	4.05%
Net profit	1.46B	81.15%
EBITDA	2.26B	3.96%

Fundamentals

Metric	Value
Market capitalization	€13.65B
Number of shares	225.37M
52-week high/low	€85.12 - €49.48
Dividend yield	5.08%
Dividends TTM	€3.08
Beta	0.53
P/E ratio	36.93
PEG ratio	-1.15
P/B ratio	7.63
P/S ratio	3.59

Company profile

Coloplast A/S entwickelt, fertigt und vertreibt medizinische Produkte. Das Unternehmen befasst sich mit der Entwicklung, der Vermarktung und dem Verkauf von Produkten und Dienstleistungen für die Intimpflege, die sich an Menschen mit Krankheiten privater und persönlicher Natur richten. Die Tätigkeit des Unternehmens ist in vier Geschäftsbereiche gegliedert: Ostomy Care mit Produkten für Menschen, deren Darmausgang durch die Bauchdecke umgeleitet wurde, Continence Care für Menschen, die an Erkrankungen und Schäden des Harnsystems leiden, Urology Care für Menschen, die an Erkrankungen und Schäden der Nieren, des Harnsystems oder des männlichen Fortpflanzungssystems leiden und Wound & Skin Care für die Behandlung chronischer Wunden und Hautpflegeprodukte zur Prävention und Behandlung. Das Unternehmen liefert Produkte an Krankenhäuser, Institutionen sowie Großhändler und Apotheken.

Name	COLOPLAST
CEO	Gavin Wood
Headquarters	Humlebæk, ze Denmark
Website	coloplast.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	01/24/2007
Employees	16,907